Refludan Prescription Drug Pharmaceutical Information

This page provides details of the prescription pharmacy drug Refludan. For further information please click one of the links below:

Pharmacy Drug Brand Name: Refludan®
Active Ingredient(s): lepirudin (rDNA)
Strength(s) / Dose(s): 50mg/vial
Delivery / Dosage Form(s): Injection
Company Manufacturer Name: Hoechst Marion Roussel, Inc.
Availability / Prescription: Prescription only
Date Approved by FDA *: March 6, 1998

* Approval by the FDA does not necessarily mean that this drug is available for consumers at this time.

What is Refludan used for?

Refludan is indicated for patients who have had a reaction to heparin that resulted in reduced platelets and associated blood clots, in order to prevent more clotting complications

Who should not be treated with Refludan? You should not be given Refludan if you are allergic to this drug or similar drugs.

Special Warnings for Refludan:

Bleeding is the most common complication of Refludan. If you have the following conditions, your risk of bleeding may be increased:

General Precautions with Refludan:

What should I tell my doctor or health care (healthcare) provider?

Because certain other medications can interact with Refludan, and increase the risk of bleeding, review all medications that you are taking with your health care (healthcare) provider, including those that you take without a prescription. Other drugs that break up or dissolve clots, such as (rt-PA) or streptokinase, or drugs that prevent clots such as Coumadin, warfarin, or aspirin, can increase your risk of bleeding.

What are some possible side effects of Refludan? (This is not a comprehensive list of possible side effects assosciated with Refludan. Your doctor or pharmacist can provide expert advice on the possible side effects of this drug.)

Bleeding was the most common adverse event reported during testing of the product. Bleeding can be severe.

Other side effects occurring in at least 2% of the people studied:

Copyright © www.TheDrugLibrary.com :: site map